ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SYNC Syncona Limited

124.00
1.20 (0.98%)
Last Updated: 11:50:43
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.20 0.98% 124.00 122.60 124.00 124.00 122.60 122.60 254,260 11:50:43
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.76 826.75M

Syncona Limited Total Voting Rights

31/08/2018 4:08pm

UK Regulatory


 
TIDMSYNC 
 
Syncona Limited 
 
                              Total Voting Rights 
 
31 August 2018 
 
Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 
August 2018 the total number of ordinary shares in issue now stands at 
661,222,309 and the total number of voting rights in the Company is 661,222,309 
ordinary shares. 
 
The Company does not hold any ordinary shares in treasury. 
 
The above figure may be used by shareholders as the denominator for the 
calculations by which they will determine if they are required to notify their 
interest in, or a change to their interest in, the Company under the FCA's 
Disclosure and Transparency Rules. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Annabel Clay 
Tel: +44 (0) 20 7611 2031 
 
Northern Trust International Fund Administration Services (Guernsey) Limited 
Company Secretary 
Tel: 01481 745001 
 
Copies of this press release and other corporate information can be found on 
the company website at: www.synconaltd.com 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. 
 
We take a long-term view, underpinned by a deep pool of capital, and are 
established leaders in gene and cell therapy. We focus on delivering dramatic 
efficacy for patients in areas of high unmet need. 
 
 
 
END 
 

(END) Dow Jones Newswires

August 31, 2018 11:08 ET (15:08 GMT)

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock